|
1
|
Almeida AM and Ramos F: Acute myeloid
leukemia in the older adults. Leuk Res Rep. 6:1–7. 2016.PubMed/NCBI
|
|
2
|
Papaemmanuil E, Gerstung M, Bullinger L,
Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F,
Bolli N, et al: Genomic classification and prognosis in acute
myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lagunas-Rangel FA, Chavez-Valencia V,
Gomez-Guijosa MA and Cortes-Penagos C: Acute myeloid
leukemia-genetic alterations and their clinical prognosis. Int J
Hematol Oncol Stem Cell Res. 11:328–339. 2017.PubMed/NCBI
|
|
4
|
Short NJ, Rytting ME and Cortes JE: Acute
myeloid leukaemia. Lancet. 392:593–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hobbs GA, Der CJ and Rossman KL: RAS
isoforms and mutations in cancer at a glance. J Cell Sci.
129:1287–1292. 2016.PubMed/NCBI
|
|
6
|
Ward AF, Braun BS and Shannon KM:
Targeting oncogenic Ras signaling in hematologic malignancies.
Blood. 120:3397–3406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kadia TM, Kantarjian H, Kornblau S,
Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G,
Pierce S, Cortes J and Ravandi F: Clinical and proteomic
characterization of acute myeloid leukemia with mutated RAS.
Cancer. 118:5550–5559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Steelman LS, Franklin RA, Abrams SL,
Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P,
Nicoletti F, et al: Roles of the Ras/Raf/MEK/ERK pathway in
leukemia therapy. Leukemia. 25:1080–1094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kornblau SM, Womble M, Qiu YH, Jackson CE,
Chen W, Konopleva M, Estey EH and Andreeff M: Simultaneous
activation of multiple signal transduction pathways confers poor
prognosis in acute myelogenous leukemia. Blood. 108:2358–2365.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steelman LS, Abrams SL, Whelan J, Bertrand
FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A,
et al: Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and
Jak/STAT pathways to leukemia. Leukemia. 22:686–707. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cox AD, Fesik SW, Kimmelman AC, Luo J and
Der CJ: Drugging the undruggable RAS: Mission possible? Nat Rev
Drug Discov. 13:828–851. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coombs CC, Tallman MS and Levine RL:
Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol.
13:305–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kavanagh S, Murphy T, Law A, Yehudai D, Ho
JM, Chan S and Schimmer AD: Emerging therapies for acute myeloid
leukemia: Translating biology into the clinic. JCI Insight.
2:e956792017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu S, Jang H, Gu S, Zhang J and Nussinov
R: Drugging Ras GTPase: A comprehensive mechanistic and signaling
structural view. Chem Soc Rev. 45:4929–4952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schmieder R, Puehler F, Neuhaus R, Kissel
M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K and Scholz A:
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in
combination with sorafenib exhibits antitumor activity in
preclinical murine and rat models of hepatocellular carcinoma.
Neoplasia. 15:1161–1171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dickson MA, Gordon MS, Edelman G, Bendell
JC, Kudchadkar RR, LoRusso PM, Johnston SH, Clary DO and Schwartz
GK: Phase I study of XL281 (BMS-908662), a potent oral RAF kinase
inhibitor, in patients with advanced solid tumors. Invest New
Drugs. 33:349–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mendzelevski B, Ferber G, Janku F, Li BT,
Sullivan RJ, Welsch D, Chi W, Jackson J, Weng O and Sager PT:
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc
interval in patients with advanced solid tumor malignancies. Cancer
Chemother Pharmacol. 81:1129–1141. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ryan MB and Corcoran RB: Therapeutic
strategies to target RAS-mutant cancers. Nat Rev Clin Oncol.
15:709–720. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Borthakur G, Popplewell L, Boyiadzis M,
Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A,
Giagounidis A, et al: Activity of the oral mitogen-activated
protein kinase kinase inhibitor trametinib in RAS-mutant relapsed
or refractory myeloid malignancies. Cancer. 122:1871–1879. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jain N, Curran E, Iyengar NM, Diaz-Flores
E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP,
Green M, et al: Phase II study of the oral MEK inhibitor
selumetinib in advanced acute myelogenous leukemia: A University of
Chicago phase II consortium trial. Clin Cancer Res. 20:490–498.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maiti A, Naqvi K, Kadia TM, Borthakur G,
Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, et
al: Phase II trial of MEK inhibitor binimetinib (MEK162) in
RAS-mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk.
19:142–148. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peng SB, Henry JR, Kaufman MD, Lu WP,
Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, et al:
Inhibition of RAF isoforms and active dimers by LY3009120 leads to
anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell.
28:384–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Keum H, Kim TW, Kim Y, Seo C, Son Y, Kim
J, Kim D, Jung W, Whang CH and Jon S: Bilirubin nanomedicine
alleviates psoriatic skin inflammation by reducing oxidative stress
and suppressing pathogenic signaling. J Control Release.
325:359–369. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee SH, Kim DK, Seo YR, Woo KM, Kim CS and
Cho MH: Nickel (II)-induced apoptosis and G2/M enrichment. Exp Mol
Med. 30:171–176. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang HM, Chen CY and Wu PF:
Isophilippinolide A arrests cell cycle progression and induces
apoptosis for anticancer inhibitory agents in human melanoma cells.
J Agric Food Chem. 62:1057–1065. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao L, Au JL and Wientjes MG: Comparison
of methods for evaluating drug-drug interaction. Front Biosci
(Elite Ed). 2:241–249. 2010.PubMed/NCBI
|
|
29
|
Kufe DW, Griffin JD and Spriggs DR:
Cellular and clinical pharmacology of low-dose ara-C. Semin Oncol.
12 (Suppl 3):S200–S207. 1985.
|
|
30
|
Spriggs D, Griffin J, Wisch J and Kufe D:
Clinical pharmacology of low-dose cytosine arabinoside. Blood.
65:1087–1089. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen L, Guo P, Zhang Y, Li X, Jia P, Tong
J and Li J: Autophagy is an important event for low-dose cytarabine
treatment in acute myeloid leukemia cells. Leuk Res. 60:44–52.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Z, Chen J, Wang H, Ding K, Li Y, de
Silva A, Sehgal V, Burbano JL, Sundararaj R, Gamage J, et al:
Chidamide shows synergistic cytotoxicity with cytarabine via
inducing G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Am J Transl Res. 9:5631–5642. 2017.PubMed/NCBI
|
|
33
|
Vakana E, Pratt S, Blosser W, Dowless M,
Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, et al:
LY3009120, a panRAF inhibitor, has significant anti-tumor activity
in BRAF and KRAS mutant preclinical models of colorectal cancer.
Oncotarget. 8:9251–9266. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tambe M, Karjalainen E, Vähä-Koskela M,
Bulanova D, Gjertsen BT, Kontro M, Porkka K, Heckman CA and
Wennerberg K: Pan-RAF inhibition induces apoptosis in acute myeloid
leukemia cells and synergizes with BCL2 inhibition. Leukemia.
34:3186–3196. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hall-Jackson CA, Eyers PA, Cohen P,
Goedert M, Boyle FT, Hewitt N, Plant H and Hedge P: Paradoxical
activation of Raf by a novel Raf inhibitor. Chem Biol. 6:559–568.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hatzivassiliou G, Song K, Yen I,
Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor
SL, Vigers G, et al: RAF inhibitors prime wild-type RAF to activate
the MAPK pathway and enhance growth. Nature. 464:431–435. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
King AJ, Patrick DR, Batorsky RS, Ho ML,
Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, et al:
Demonstration of a genetic therapeutic index for tumors expressing
oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res.
66:11100–11105. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei AH, Strickland SA Jr, Hou JZ, Fiedler
W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, et al:
Venetoclax combined with low-dose cytarabine for previously
untreated patients with acute myeloid leukemia: Results from a
phase Ib/II study. J Clin Oncol. 37:1277–1284. 2019. View Article : Google Scholar : PubMed/NCBI
|
